Canaccord Reiterates Buy Rating on Ionis Pharmaceuticals (IONS)

August 24, 2026 6:40 AM

Canaccord analyst Gary Nachman reiterated a Buy rating and $95.00 price target on Ionis Pharmaceuticals (NASDAQ: IONS).The analyst commented: "We ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found